TSX:CRDL

FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com

SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Administration (FDA) recently approved an Investigational New Drug application by Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) that opens the door for Cardiol to conduct its Phase IIIII trial. The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).

Heart Issues and COVID

The US Centers for Disease Control (CDC) lists pre-existing serious heart conditions as a major risk factor for COVID-19 patients. The CDC provided data for cases in the US through May, and found that 45% of hospitalized patients had underlying conditions, with CVD the most common of these at 32%. The European Society of Cardiology notes that the body's inflammatory response to the COVID-19 viral infection can stress the cardiovascular system and warns that, "Individuals with heart conditions, such as heart failure, dilated cardiomyopathy, advanced forms of arrhythmogenic right ventricular cardiomyopathy and patients with congenital cyanotic heart disease are at highest risk."

To be clear, CVD does not increase the chances of being infected, but rather increases the chances of severe complications should one become infected. COVID was originally thought to be primarily a respiratory disease, but the link to heart conditions has the scientific community scrambling to precisely identify the nature of that link and to come up with treatments that can improve outcomes for these patients.

Cardiol's Potential Therapy

Cardiol Therapeutics is a Canadian company started and run by a team of cardiovascular disease experts. The CEO, David Elsley, founded Vasogen, Inc. back in 1990 to develop therapies for heart failure and other inflammatory conditions. CMO Dr. Eldon R. Smith was the Editor-in-Chief of the Canadian Journal of Cardiology following a long stint at the University of Calgary as Head of Cardiology and Dean of Medicine.

The company took note of a wealth of clinical evidence suggesting that CBD demonstrates anti-inflammatory properties that could prove effective in treating inflammation-related heart conditions such as acute myocarditis and heart failure. Following its own pre-clinical studies, Cardiol is even more convinced of the potential value of CBD. The company is developing a patented subcutaneous formulation to improve the bioavailability of CBD.

Cardiol formed a clinical trial pipeline to investigate CBD as a treatment for acute myocarditis (Phase 1 launched in August 2020) and heart failure. Along the way, the company noticed the connection between CVD and severe COVID-19 outcomes, filing a patent in early May 2020 to cover "the administration of CBD to reduce the severity of disease in COVID-19 patients with pre-existing cardiovascular conditions, and to prevent the progression of such conditions."

Cardiol's Phase II/III trial will be conducted at major centers in the United States, where the prevalence of COVID-19 remains high and will be overseen by an independent steering committee, consisting of an impressive collection of inflammatory heart disease experts: Dr. Dennis McNamara (Chair), Professor of Medicine and Director of the Heart Failure/Transplantation Program, University of Pittsburgh; Dr. Leslie Cooper (Co-Chair), Chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine and Chair of the Department of Cardiovascular Medicine, Mayo Clinic; Dr. Arvind Bhimaraj, Medical Director, Advanced Heart Failure, Mechanical Circulatory Support and Heart Transplant Programs, Houston Methodist Hospital; Dr. Barry Trachtenberg, Director, Cardio-Oncology and Cardiac Amyloid Programs, Associate Director, Mechanical Circulatory Support Program, Houston Methodist Hospital; Dr. Wilson Tang, Director of the Center for Clinical Genomics, Research Director, and staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic; Dr. Peter Liu, Chief Scientific Officer and Vice President of Research, University of Ottawa Heart Institute; Dr. Carsten Tschöpe, Vice Director of the Dept. of Cardiology, Charité University Medicine Berlin, Germany; Dr. Matthias Friedrich, Professor of Medicine and Chief, Cardiovascular Imaging, McGill University Health Centre.

Where It's Headed

The hope is to prove efficacy "in preventing cardiovascular and pulmonary complications in hospitalized patients, with a confirmed diagnosis of COVID-19 within the previous 24 hours, and who have pre-existing CVD and/or significant risk factors for CVD." The successful IND application provides Cardiol an expedited regulatory approval process that should not only shorten the duration of the clinical program from start to finish but also reduce costs from a standard clinical program.

Cardiol expects to initiate the trial in Q4 with results expected in H2 2021. Along with the company's Phase I trial in Canada, expected to wrap up by the end of 2020 and intended to support a Phase II international trial for the efficacy of CBD as a treatment for acute myocarditis, this trial represents a major potential catalyst for the company's stock in the coming months. Simultaneously, Cardiol anticipates the imminent launch of its pharmaceutical CBD product into the Canadian market in collaboration with Shoppers Drug Mart, representing a major commercial revenue opportunity for the company. Investors might want to keep an eye on Cardiol Therapeutics for more developments as the company tends to its several oars in the water.

Please follow the link to read the full article: https://www.secfilings.com/news/fda-approves-landmark-covidheartcbd-clinical-trial-174/

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members.

Disclaimer

SECFilings.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.secfilings.com (the 'Site') is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. SECFilings.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. SECFilings.com received compensation for producing and presenting high quality and sophisticated content on SECFilings.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns SECFilings.com, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.secfilings.com/legal/disclaimer.

Paul Archie
406.862.2242
parchie@tdmfinancial.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64934

News Provided by Newsfile via QuoteMedia

Cardiol Therapeutics

Cardiol Therapeutics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less

AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE

Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon executive vice president of Global Commercial Operations at Amgen, Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani executive vice president of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, and Paul Burton senior vice president and chief medical officer at Amgen, will participate in the conference call. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Provides Update on Loan

Sirona Biochem Provides Update on Loan

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the " Amended Note ") with 0906462 B.C. Ltd. (the " Lender "). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the " Loan "). Pursuant to the terms and conditions of the Amended Note:

(a)   the Loan is repayable on demand by the Lender at any time following the one-year anniversary of the date of the applicable advance;

(b)   the Loan bears interest at a rate of 12% per annum, calculated yearly not in advance; and

(c)   the Company has agreed to, subject to TSX Venture Exchange approval (" TSXV Approval "), issue the Lender 450,000 common shares in the capital of the Company (" Bonus Shares ") at a price of $0.12 per Bonus Share, as consideration for the risks taken by the Lender in providing the Company the Loan.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") has announced its partnership with Global Beauty Consulting Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMim TM in anticipation of its launch in the first quarter of 2025.

GBC has a history of working with Sirona Biochem on the formulation of TFC-1067 for clinical development. This new venture is pivotal in building a brand and competitive product line that showcases GlycoProteMim's potent anti-aging benefits through its exclusive distribution brand Sirona Laboratories TM .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Eyes 2025 Launch of New Anti-aging Product

Sirona Biochem Eyes 2025 Launch of New Anti-aging Product

Following successful clinical trials for its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, Sirona Biochem (TSXV:SBM) is pursuing a path to commercialization for a final cosmetic product, according to the company’s chief scientific officer, Géraldine Deliencourt-Godefroy.

“We are still pursuing a final compound to launch on the market, which is pretty good because it will allow us to have a better control on the final product. We can launch fast on the market, we can generate revenue earlier and also the level of revenue will be higher,” Deliencourt-Godefroy said.

Sirona has already trademarked its anti-aging skincare ingredient, GlycoProteMim, as one of the first steps for commercialization. In January of this year, the company also launched a new cosmetics subsidiary, Sirona Laboratories, which is dedicated to maximizing the commercial potential of GlycoProteMim.

Keep reading...Show less

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

- Amgen (NASDAQ:AMGN) will present at the 34 th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday Feb. 14, 2024. Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney senior vice president of Global Marketing, Access and Capabilities at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
male doctor holding cell phone

How Big Tech is Helping Leverage Big Data in Healthcare

The use of artificial intelligence (AI) and machine learning in healthcare was a prominent theme discussed at this year's Biotech Showcase, a three day event held in San Francisco in January.

While experts agree that Big Tech has the potential to improve patient outcomes by revolutionizing the way illnesses are diagnosed and treated, there are also challenges and ethical considerations when implementing AI in healthcare.

The Investing News Network sat in on several Biotech Showcase discussions on the role of AI and machine learning in healthcare, as well as the impact of digital medicine. These talks shed light on the opportunities and challenges of bringing these industries together, and explored strategies for overcoming obstacles and maximizing the benefits of these technologies. Read on to learn about key takeaways from the event.

Keep reading...Show less
Cardiol Therapeutics

Cardiol Therapeutics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×